Haematology Treatments at GoBroad Healthcare Group, China
China's most research-active haematology network, 8 state-of-the-art research hospitals in Beijing, Shanghai, and Guangzhou.
Treats relapsed leukaemia, thalassemia, lymphoma and more in adults and children.
Why International Patients Choose GoBroad for Haematology Treatment in China
China's most experienced hospital network for relapsed and refractory blood cancer and haematological disorders.
- 4,000+ stem cell transplants completed, from children aged 1 month to adults aged 75
- 90%+ complete remission rate for relapsed B-cell leukaemia using CAR-T cell therapy.
- 1,223 paediatric HSCTs at the Guangdong Chunfu Centre (2018 to 2024); 97.84% thalassemia OS.
- Second allogeneic transplant programme achieves 1-year OS of 80.6%, above international benchmarks.
- Patients treated from Kazakhstan, Russia, the Middle East, Belgium, New Zealand, the UK, and Germany.
Haematology Diagnostic and Treatment Technology at GoBroad
- Flow cytometry analysis
- Next-generation sequencing (NGS)
- FISH and chromosome testing
- Mass spectrometry diagnostics
- Siemens 3.0T MRI
- Siemens 64-slice CT
Haematology Treatments at GoBroad Hospitals in China
Each treatment plan is built on individual diagnosis, disease history, and risk profile, following international clinical standards.
Haematopoietic stem cell transplantation (HSCT)
Replaces damaged blood-forming cells with healthy donor or patient stem cells.
Inquire
Gene therapy
Corrects the genetic defect behind thalassemia or sickle cell disease at the stem cell level, in one treatment.
Inquire
Precision Diagnostics (MICM)
5-module diagnostic system analysing morphology, immunology, cytogenetics, and molecular biology.
Inquire
Care Journey for International Patients
Your cancer treatment journey made simple and stress-free in 5 easy steps
-
1
Online inquiry & medical files upload Share your medical reports for review. It takes less than a minute.
-
2
Doctor review & treatment plan Within 24hrs you will receive treatment options & a preliminary plan before travel.
-
3
Travel coordination We arrange your visa, flights, and accommodation.
-
4
Treatment phase Full care under a dedicated case manager.
-
5
Start your treatment Begin treatment with full support from our care team.
Frequently Asked Questions
Have a question? Our support team is here to guide you through each step of your treatment journey with personal care and attention.Does GoBroad treat children with leukaemia, thalassemia, or other blood disorders?
GoBroad Healthcare Group has one of China's most recognised paediatric haematology programmes.
The Nanfang-Chunfu Children's Institute of Hematology in Guangdong, led by Professor Chunfu Li in strategic cooperation with Mayo Clinic, performed 1,223 haematopoietic stem cell transplantations in children between July 2018 and January 2024.
Paediatric transplants cover children from as young as one month of age. The team treats
- ALL
- AML
- Juvenile myelomonocytic leukaemia (JMML)
- Thalassemia
- Diamond-Blackfan anaemia
- Rare immune disorders
Results including a paediatric thalassemia overall survival rate of 97.84%.
How do I contact the international patient support team for haematology treatment at GoBroad?
Haematology appointments, treatment planning, and consultations at GoBroad Healthcare Group in China are coordinated through the International Patient Care team at My1Health, which supports international patients before, during, and after travel.
- WhatsApp: +1 718 550 0880
- Telephone: +1 718 550 0880
- Email: [email protected]
The team is available to arrange in-person appointments, online video consultations, second medical opinions, and full treatment coordination with GoBroad's haematology specialists, including cost estimates before you travel.
How long will I need to stay in China for haematology treatment?
Length of stay depends on the treatment. CAR-T cell therapy requires initial hospitalisation for cell collection, manufacturing, lymphodepletion, and infusion, spanning several weeks, followed by monitoring before discharge.
Bone marrow transplantation requires a longer inpatient stay, generally 1 to 3 months, covering engraftment and early recovery.
GoBroad's international patient coordinator prepares a personalised treatment itinerary before you travel so you know the expected timeline before you commit to coming. Remote follow-up is available after you return home so ongoing monitoring does not require repeated trips.
Is CAR-T cell therapy available for international patients at GoBroad, and what are the success rates?
CAR-T cell therapy is available to international patients across GoBroad's haematology hospitals in Beijing and Shanghai.
GoBroad was among the first hospitals in China to build a systematic CAR-T programme and has performed several thousand treatments.
For relapsed or refractory B-cell acute lymphoblastic leukaemia, the CD19 CAR-T complete remission rate exceeds 90%.
For paediatric Burkitt lymphoma, a triple-target CD19/CD20/CD22 protocol achieved a 100% overall response rate in a globally reported study.
Investigator-initiated trials give patients access to multi-target and next-generation protocols not yet commercially available elsewhere.
What blood cancers and haematological conditions does GoBroad treat?
GoBroad Healthcare Group treats the full range of blood cancers and haematological disorders, including
- Acute lymphoblastic leukaemia (ALL)
- Acute myeloid leukaemia (AML)
- Chronic myeloid leukaemia (CML)
- Hodgkin and non-Hodgkin lymphoma
- Multiple myeloma
- Myelodysplastic syndromes (MDS)
- Aplastic anaemia
- Thalassemia
- Diamond-Blackfan anaemia
- Paroxysmal nocturnal haemoglobinuria (PNH)
For patients who have relapsed or become refractory after standard treatment, GoBroad's CAR-T cell therapy, TDH haploidentical transplantation, and gene therapy programmes offer options that are not widely available outside China.
What is the thalassemia transplant success rate at GoBroad and why is it different from other hospitals?
GoBroad holds the world's highest published thalassemia transplant outcomes.
The TDH transplantation protocol achieves a 97.1% engraftment rate, a 96.5% overall survival rate, and a 94.3% thalassemia-free survival rate.
The GVHD-free and thalassemia-free survival rate exceeds 80%, surpassing every other published result globally.
Professor Li Chunfu performed the world's first haploidentical stem cell transplant for thalassemia in 1999 and has continued to refine the protocol since.
For patients who are not suitable for transplantation, gene therapy using Hemo-cel is available, with patients maintaining transfusion-free status for over four years in clinical studies.
